Dr Mark Treherne

Innovate UK Council member

Mark TreherneDr Mark Treherne is a member of the Innovate UK Council.

Mark is a commercial research scientist with over 30 years’ practical experience in the discovery and diagnosis of novel treatments for diseases with complex and unmet medical needs.

He originally trained as a neuroscientist and was formerly at Pfizer, where he was responsible for research into neurodegenerative diseases in the UK. He then set up Cambridge Drug Discovery as a co-founder and Chief Executive in 1997, which was subsequently sold to a public company on the London Stock Exchange in 2001.

Since then, he has helped to raise investment and realise exits for shareholders across a variety of life sciences companies. From 2012 to 2016, Mark led UK Trade and Investment’s Life Sciences Organisation, which supported overseas investment into the UK and enabled significant exports overseas.

He has now served on the boards of multiple therapeutics, research services and diagnostics companies worldwide. Mark’s recent focus is on cancer, digital biomarkers, gene therapy and stem cells.

He has a particular interest developing approaches such as the use of predictive validity and other related measurements to predict future outcomes, particularly in relation to the use of data science and pre-clinical disease models to better predict more efficacious and safe treatments.

Last updated: 1 September 2023

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services.